BioSpace News Archive

Genetown

Pear Therapeutics to Participate in Upcoming Investor Conferences - Apr 05, 2022

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines, called prescription digital therapeutics, announced management will participate in the following upcoming virtual investor conferences in April 2022.

April 5, 2022
·
2 min read
Business

858 Therapeutics Expands Board of Directors and Leadership Team

858 Therapeutics today announced the strengthening of its board of directors and leadership team in preparation for its next stage of growth.

April 5, 2022
·
3 min read
Drug Development

VBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program

VBI Vaccines Inc. today announced updated clinical and preclinical data from its coronavirus program, VBI-2900.

April 5, 2022
·
8 min read
Business

Catamaran Bio Appoints Frank Lee as Chair of Its Board of Directors

Catamaran Bio , Inc. today announced the appointment of Frank Lee as Chair of its Board of Directors.

April 5, 2022
·
3 min read
Biotech Bay

Cutera Announces First Patient Treated with FDA Cleared AviClear™ Acne Device

CUTERA, INC. today announced that the first patient outside of clinical trials was treated with AviClear, the only device cleared by the FDA for the treatment of mild, moderate, and severe acne.

April 5, 2022
·
3 min read
Pharm Country

Oramed Granted NASH Patent in Europe

Oramed Pharmaceuticals Inc. today announced that the European Patent Office has granted the Company the patent titled “Methods and Compositions for Treating NAFLD, Hepatic Steatosis, and Sequelae Thereof.”

April 5, 2022
·
4 min read
Pharm Country

KSL Diagnostics, Inc. Launches First-of-its-Kind Antibody Test That Measures Degree of Immunity from COVID-19

KSL Diagnostics, Inc. has launched a first-of-its-kind antibody test that detects an individual’s immune response to COVID-19 and assesses the risk of infection if subsequently exposed.

April 5, 2022
·
5 min read
Biotech Bay

Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC)

Agilent Technologies Inc. (NYSE: A) today announced CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx immunohistochemical assay to extend the use of the test to patients diagnosed with muscle-invasive urothelial carcinoma (MIUC).

April 5, 2022
·
2 min read
Biotech Bay

Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma

Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma.

April 5, 2022
·
3 min read
Genetown

Agenus’ CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead

Agenus Inc., an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and infections, announced receipt of a $5M clinical milestone payment for AGEN2373.

April 5, 2022
·
4 min read